Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0WGCDI
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
Oberotatug ravtansine
|
|||||
| Synonyms |
oberotatug ravtansine; MEN1309; OBT076
Click to Show/Hide
|
|||||
| Organization |
Oxford BioTherapeutics (Originator);Menarini
|
|||||
| Drug Status |
Phase 1
|
|||||
| Drug-to-Antibody Ratio |
3.7
|
|||||
| Structure |
|
|||||
|
|
||||||
| Antibody Name |
Oberotatug
|
Antibody Info | ||||
| Antigen Name |
Lymphocyte antigen 75 (LY75)
|
Antigen Info | ||||
| Payload Name |
DM4
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
N-succinimidyl 4-(2-pyridyldithio) butanoate (SPDB)
|
Linker Info | ||||
| Conjugate Type |
Random Lysines
|
|||||
| Combination Type |
ravtansine
|
|||||
The indication landscape of This ADC(2027 Update)
The clinical trial pipeline of This ADC(2027 Update)
| Indication | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | New Drug Application | Approved | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Breast cancer |
1 Trials
|
|||||||||
| Head and neck cancer |
2 Trials
|
|||||||||
| Lung cancer |
1 Trials
|
|||||||||
| Unspecific non-hodgkin lymphoma |
1 Trials
|
|||||||||
| Unspecific solid tumor |
2 Trials
|
|||||||||
| Urothelial cancer |
1 Trials
|